Why don’t we rely exclusively on CEA estimates to make drug coverage determinations?

Cost effectiveness analyses (CEA) typically analyses the value of a new treatment relative to its cost. If the value of the additional health benefits outweigh the additional cost, then they should be covered; if the additional cost outweighs the additional benefit, then it should not be covered, right? There are a few issues with this […]